nivolumab,ipilimumab,cabozantinib
bms,exelixis
['rcc,(-irccs),(-srcc),(-urcc)', 'cosmic313']
#esmo22 #cosmic313 orr 43% vs 36% with 3% cr in both arms; mdor not reached in either arm #rcc 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge